Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Ophthalmology Drugs in Phase III Clinical Development

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Novartis Pharmaceuticals Corporation

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI India 2021

              Participation Not Confirmed

              Update your events

              Novartis Reports Positive Topline Results From Second Phase III trial of Beovu® in Patients with Diabetic Macular Edema

              Contact the Supplier

              Lead Product(s): Brolucizumab

              Therapeutic Area: Ophthalmology Product Name: Beovu

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 15, 2020

              Details:

              In Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52).

              Nicox SA

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI India 2021

              Participation Not Confirmed

              Update your events

              Nicox Raises €15 million in Private Placement

              Contact the Supplier

              Lead Product(s): NCX 470

              Therapeutic Area: Ophthalmology Product Name: NCX 470

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: HBM Healthcare Investments

              Deal Size: $18.1 million Upfront Cash: Undisclosed

              Deal Type: Financing December 04, 2020